answersLogoWhite

0

Solanezumab is a monoclonal antibody that was developed by Eli Lilly and Company. It specifically targets amyloid-beta peptides, which are associated with the formation of amyloid plaques in the brains of Alzheimer's disease patients. The antibody was designed to bind to soluble forms of amyloid-beta, aiming to modify the disease's progression. Its development was part of ongoing research into potential therapies for Alzheimer's.

User Avatar

AnswerBot

1mo ago

What else can I help you with?